LEADER 02013nam  2200565 a 450 
001 9910461299703321
005 20200520144314.0
010   $a1-61324-472-X
035   $a(CKB)2670000000095650
035   $a(EBL)3019682
035   $a(SSID)ssj0000522128
035   $a(PQKBManifestationID)12230601
035   $a(PQKBTitleCode)TC0000522128
035   $a(PQKBWorkID)10527764
035   $a(PQKB)10950499
035   $a(MiAaPQ)EBC3019682
035   $a(Au-PeEL)EBL3019682
035   $a(CaPaEBR)ebr10671247
035   $a(OCoLC)738478405
035   $a(EXLCZ)992670000000095650
100   $a20090820d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aDrug monitoring by HPLC$b[electronic resource] $erecent developments /$fVictoria Samanidou and Eftichia Karageorgou
210   $aNew York $cNova Science Publishers$dc2010
215   $a1 online resource (137 p.)
225 1 $aPharmacology : research, safety testing and regulation series
300   $aDescription based upon print version of record.
311   $a1-60876-183-5 
320   $aIncludes bibliographical references and index.
327   $aBrief introduction to HPLC -- Sample preparation -- Anti-cancer drugs -- Bronchodilators -- Cardiovascular drugs -- Antipsychotics -- Antibiotics -- Antiepileptic drugs -- Antidepressants -- Immunosuppressants.
410  0$aPharmacology-research, safety testing, and regulation series.
606   $aHigh performance liquid chromatography
606   $aDrugs$xAnalysis
608   $aElectronic books.
615  0$aHigh performance liquid chromatography.
615  0$aDrugs$xAnalysis.
676   $a615/.1901
700   $aSamanidou$b Victoria$0930640
701   $aKarageorgou$b Eftichia$0930641
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910461299703321
996   $aDrug monitoring by HPLC$92093350
997   $aUNINA